Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free QTTB Stock Alerts

Q32 Bio (QTTB) Financials

Q32 Bio logo
$11.47 -1.12 (-8.90%)
As of 09:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Q32 Bio

Annual Income Statements for Q32 Bio

This table shows Q32 Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -30 -56 -104 -129 -96 -5.01 -54 -48 30
Consolidated Net Income / (Loss)		 -30 -56 -104 -129 -96 -5.01 -54 -48 30
Net Income / (Loss) Continuing Operations		 -30 -56 -104 -129 -96 -5.01 -54 -48 30
Total Pre-Tax Income 		-30 -56 -104 -129 -96 1.20 -53 -46 30
Total Operating Income		 -30 -60 -110 -130 -96 -133 -48 -66 17
Total Gross Profit		 0.00 5.32 1.67 2.70 34 3.21 -6.65 0.00 54
Total Revenue		 0.00 5.32 1.67 2.70 34 3.21 -6.65 0.00 54
Operating Revenue		 0.00 5.32 1.67 2.70 34 3.21 -6.65 0.00 54
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 30 65 112 133 130 136 42 66 37
Selling, General & Admin Expense		 8.28 17 22 33 37 38 9.88 18 18
Research & Development Expense		 21 48 89 100 93 98 32 48 19
Total Other Income / (Expense), net		 -0.33 4.35 6.03 1.57 0.19 134 -5.17 20 13
Interest & Investment Income		 0.54 4.35 6.03 1.57 0.19 3.23 - - 0.00
Other Income / (Expense), net		 -0.88 - - - 0.00 131 -5.17 20 13
Income Tax Expense		 - - - - 0.00 0.72 0.32 0.02 0.00
Basic Earnings per Share		 ($12.10) ($1.95) ($2.47) ($2.80) ($1.73) ($0.09) ($153.96) ($5.12) $2.42
Weighted Average Basic Shares Outstanding		 2.48M 28.55M 42.12M 45.91M 55.28M 57.40M 349.06K 9.32M 12.30M
Diluted Earnings per Share		 ($12.10) ($1.95) ($2.47) ($2.80) ($1.73) ($0.09) ($153.96) ($6.58) $2.42
Weighted Average Diluted Shares Outstanding		 2.48M 28.55M 42.12M 45.91M 55.28M 57.40M 349.06K 9.66M 12.31M
Weighted Average Basic & Diluted Shares Outstanding		 2.48M 28.55M 42.12M 45.91M 55.28M 57.68M 58.13M 12.20M 14.63M

Quarterly Income Statements for Q32 Bio

This table shows Q32 Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -27 1.03 -17 -18 -14 -11 -9.49 -7.39 58 -7.61
Consolidated Net Income / (Loss)		 -14 -27 1.03 -17 -18 -14 -11 -9.49 -7.39 58 -7.61
Net Income / (Loss) Continuing Operations		 -14 -27 1.03 -17 -18 -14 -11 -9.49 -7.39 58 -7.61
Total Pre-Tax Income 		-14 -27 1.21 -16 -18 -14 -11 -9.49 -7.39 58 -7.61
Total Operating Income		 -7.80 -26 -15 -18 -19 -15 -12 -9.17 -7.58 46 -7.72
Total Gross Profit		 1.86 -15 0.00 0.00 0.00 - 0.00 0.00 0.00 54 0.00
Total Revenue		 1.86 -15 0.00 0.00 0.00 - 0.00 0.00 0.00 54 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 9.66 11 15 18 19 15 12 9.17 7.58 7.86 7.72
Selling, General & Admin Expense		 2.19 2.81 5.00 4.51 4.47 3.98 5.10 4.01 4.02 4.54 4.50
Research & Development Expense		 7.46 8.34 9.84 13 14 11 7.12 5.16 3.56 3.32 3.22
Total Other Income / (Expense), net		 -6.17 -1.01 16 2.39 1.22 0.36 1.20 -0.32 0.19 12 0.11
Other Income / (Expense), net		 -6.17 -1.01 16 2.39 1.22 0.36 1.20 -0.32 0.19 12 0.11
Basic Earnings per Share		 ($40.52) ($77.54) $1.03 ($1.42) ($1.46) ($1.52) ($0.90) ($0.78) ($0.60) $4.69 ($0.54)
Weighted Average Basic Shares Outstanding		 346.29K 349.06K 995.28K 11.96M 12.08M 9.32M 12.20M 12.20M 12.24M 12.30M 14.10M
Diluted Earnings per Share		 ($40.52) ($77.54) ($6.33) ($1.42) ($1.46) ($1.52) ($0.90) ($0.78) ($0.60) $4.69 ($0.54)
Weighted Average Diluted Shares Outstanding		 346.29K 349.06K 2.33M 11.96M 12.08M 9.66M 12.20M 12.20M 12.24M 12.31M 14.10M
Weighted Average Basic & Diluted Shares Outstanding		 57.93M 58.13M 11.94M 12.06M 12.18M 12.20M 12.20M 12.20M 12.30M 14.63M 16.96M

Annual Cash Flow Statements for Q32 Bio

This table details how cash moves in and out of Q32 Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 40 -13 15 164 -108 -76 -18 47 -30
Net Cash From Operating Activities		 6.48 -43 -91 -94 -110 -114 -19 -68 -34
Net Cash From Continuing Operating Activities		 6.48 -43 -91 -94 -112 -114 -19 -68 -34
Net Income / (Loss) Continuing Operations		 -30 -56 -104 -129 -96 -5.01 -54 -48 30
Consolidated Net Income / (Loss)		 -30 -56 -104 -129 -96 -5.01 -54 -48 30
Depreciation Expense		 0.68 1.29 6.32 7.97 8.35 1.29 0.50 0.49 0.39
Amortization Expense		 -0.09 -1.59 - -0.20 -0.89 -1.95 0.09 -0.03 0.18
Non-Cash Adjustments To Reconcile Net Income		 0.28 2.75 5.78 15 19 -111 8.17 -8.63 -60
Changes in Operating Assets and Liabilities, net		 36 11 0.46 12 -42 3.35 26 -12 -4.41
Net Cash From Investing Activities		 -82 -122 -52 205 -51 37 -0.01 20 7.00
Net Cash From Continuing Investing Activities		 -82 -122 -52 205 -51 37 -0.01 20 7.00
Purchase of Property, Plant & Equipment		 -1.96 -25 -22 -3.73 -2.40 -1.29 -0.01 -0.08 0.00
Sale of Property, Plant & Equipment		 - - - - - 0.00 - 0.00 7.00
Sale and/or Maturity of Investments		 0.00 148 256 229 49 65 0.00 20 0.00
Net Cash From Financing Activities		 115 151 158 53 52 0.60 0.41 95 -3.13
Net Cash From Continuing Financing Activities		 0.00 151 158 53 52 0.60 0.41 95 -3.13
Repayment of Debt		 - - - - - - -5.20 0.00 -3.13
Issuance of Debt		 - - - - - - 5.50 7.00 0.00
Issuance of Common Equity		 0.00 151 135 53 52 0.60 0.00 42 0.00
Other Financing Activities, net		 0.00 0.09 23 0.18 0.15 0.00 0.11 46 0.00

Quarterly Cash Flow Statements for Q32 Bio

This table details how cash moves in and out of Q32 Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 16 -11 85 -18 -8.58 -11 -12 -11 -5.79 -0.74 2.45
Net Cash From Operating Activities		 16 -11 -15 -22 -20 -11 -12 -11 -4.23 -6.18 -6.34
Net Cash From Continuing Operating Activities		 16 -11 -15 -22 -20 -11 -12 -11 -4.23 -6.18 -6.34
Net Income / (Loss) Continuing Operations		 -14 -27 1.03 -17 -18 -14 -11 -9.49 -7.39 58 -7.61
Consolidated Net Income / (Loss)		 -14 -27 1.03 -17 -18 -14 -11 -9.49 -7.39 58 -7.61
Depreciation Expense		 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.09 0.09 0.09 0.09
Amortization Expense		 0.01 0.03 0.03 -0.14 0.04 0.05 0.05 0.05 0.05 0.04 0.03
Non-Cash Adjustments To Reconcile Net Income		 6.69 1.86 -15 2.93 2.20 1.40 1.57 1.42 1.33 -64 1.71
Changes in Operating Assets and Liabilities, net		 23 14 -0.58 -8.15 -4.29 1.19 -3.19 -2.73 1.69 -0.19 -0.57
Net Cash From Investing Activities		 -0.00 - 0.10 9.89 9.94 -0.00 0.00 - - 7.00 0.00
Net Cash From Continuing Investing Activities		 -0.00 - 0.10 9.89 9.94 -0.00 0.00 - - 7.00 0.00
Purchase of Property, Plant & Equipment		 -0.00 - 0.00 -0.02 -0.06 -0.00 0.00 - - - 0.00
Sale and/or Maturity of Investments		 - - 0.10 9.90 10 - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.30 0.08 99 -5.52 1.00 0.32 0.00 - -1.56 -1.56 8.80
Net Cash From Continuing Financing Activities		 0.30 0.08 99 -5.52 1.00 0.32 0.00 - -1.56 -1.56 8.80
Repayment of Debt		 - - 0.00 - - - 0.00 - - -1.56 -1.56
Issuance of Debt		 5.50 - 7.00 - - - 0.00 - - - 0.00
Issuance of Common Equity		 - - 42 - - - 0.00 - - - 10
Other Financing Activities, net		 - 0.08 50 -5.52 1.00 0.32 0.00 - - - 0.00

Annual Balance Sheets for Q32 Bio

This table presents Q32 Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 138 259 311 264 212 228 47 92 62
Total Current Assets		 132 222 267 220 192 181 29 82 55
Cash & Equivalents		 52 38 54 217 108 34 26 78 48
Prepaid Expenses		 1.95 6.95 4.19 2.13 7.13 5.99 3.10 3.91 6.75
Plant, Property, & Equipment, net		 3.15 36 43 37 2.25 1.08 1.78 1.37 0.98
Total Noncurrent Assets		 2.77 1.77 1.27 7.17 18 46 17 9.09 5.75
Other Noncurrent Operating Assets		 2.77 1.77 1.27 7.17 18 46 11 8.44 5.10
Other Noncurrent Nonoperating Assets		 - - - - - - 5.65 0.65 0.65
Total Liabilities & Shareholders' Equity		 138 259 311 264 212 228 47 92 62
Total Liabilities		 39 63 52 68 42 50 119 87 20
Total Current Liabilities		 8.86 23 12 23 17 23 14 16 11
Short-Term Debt		 - - - - - - 0.88 3.10 6.24
Accounts Payable		 2.54 16 2.61 4.72 2.37 1.14 3.47 2.99 0.88
Accrued Expenses		 2.86 5.04 7.64 9.80 11 19 9.76 7.48 4.23
Total Noncurrent Liabilities		 30 40 40 45 25 28 104 70 8.42
Long-Term Debt		 - - - - - - 43 9.56 3.47
Other Noncurrent Operating Liabilities		 - - 0.00 13 24 28 61 61 4.94
Commitments & Contingencies		 0.00 0.00 - - - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -39 196 259 196 170 178 -183 5.68 42
Total Preferred & Common Equity		 -39 196 259 196 170 178 -183 5.68 42
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Total Common Equity		 -39 196 259 196 170 178 -183 5.68 42
Common Stock		 0.80 292 458 524 594 608 4.16 240 247
Retained Earnings		 -40 -96 -200 -328 -424 -429 -187 -235 -205

Quarterly Balance Sheets for Q32 Bio

This table presents Q32 Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 140 152 124 105 79 66 58 64
Total Current Assets		 107 138 112 94 69 58 51 57
Cash & Equivalents		 29 116 98 89 65 55 49 51
Prepaid Expenses		 3.02 2.73 3.97 4.82 3.15 3.49 1.77 6.45
Plant, Property, & Equipment, net		 0.00 1.66 1.55 1.49 1.25 1.16 1.07 0.89
Total Noncurrent Assets		 33 13 11 9.16 9.19 6.63 5.91 5.58
Other Noncurrent Operating Assets		 19 12 10 8.51 8.54 5.99 5.26 4.94
Other Noncurrent Nonoperating Assets		 - 0.65 0.65 0.65 0.65 0.65 0.65 0.65
Total Liabilities & Shareholders' Equity		 140 152 124 105 79 66 58 64
Total Liabilities		 52 104 91 86 83 78 76 17
Total Current Liabilities		 25 33 17 14 15 12 11 11
Short-Term Debt		 - 3.09 0.00 1.53 4.66 6.23 6.23 6.24
Accounts Payable		 7.80 4.96 2.48 1.26 2.71 0.91 0.97 0.65
Accrued Expenses		 16 20 11 8.91 5.27 4.40 3.91 3.78
Total Noncurrent Liabilities		 27 71 74 72 69 67 65 6.69
Long-Term Debt		 - 9.40 13 11 8.04 6.52 5.00 1.94
Other Noncurrent Operating Liabilities		 27 61 61 61 60 60 60 4.75
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 88 49 34 18 -4.01 -12 -18 46
Total Preferred & Common Equity		 88 49 34 18 -4.01 -12 -18 46
Preferred Stock		 0.00 - - - 0.00 0.00 0.00 0.00
Total Common Equity		 88 49 34 18 -4.01 -12 -18 46
Common Stock		 614 235 237 239 242 243 244 259
Retained Earnings		 -526 -186 -203 -221 -246 -255 -263 -213

Annual Metrics And Ratios for Q32 Bio

This table displays calculated financial ratios and metrics derived from Q32 Bio's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 37,495,773.00 44,034,647.00 45,264,419.00 57,150,274.00 57,480,610.00 57,934,332.00 12,180,701.00 12,304,352.00
DEI Adjusted Shares Outstanding		 0.00 2,083,099.00 2,446,369.00 2,514,690.00 3,175,015.00 3,193,367.00 3,218,574.00 12,180,701.00 12,304,352.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -26.68 -42.48 -51.18 -30.16 -1.57 -16.70 -3.92 2.42
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% -68.70% 62.18% 1,157.25% -90.56% -307.33% 100.00% 0.00%
EBITDA Growth		 0.00% -101.20% -72.06% -18.21% 27.76% 96.96% -1,867.20% 13.65% 166.61%
EBIT Growth		 0.00% -96.27% -83.46% -18.48% 26.34% 97.88% -2,529.18% 13.74% 164.71%
NOPAT Growth		 0.00% -102.06% -83.46% -18.48% 26.34% 19.99% 37.14% -36.98% 136.53%
Net Income Growth		 0.00% -85.31% -86.98% -23.84% 25.59% 94.77% -973.79% 11.18% 162.47%
EPS Growth		 0.00% 83.88% -26.67% -13.36% 38.21% 94.80% -973.79% 95.73% 136.78%
Operating Cash Flow Growth		 0.00% -756.92% -114.65% -3.26% -16.35% -3.56% 83.57% -262.56% 50.46%
Free Cash Flow Firm Growth		 0.00% 0.00% -66.54% 19.50% -39.05% 58.09% 164.93% -260.35% -3.33%
Invested Capital Growth		 0.00% 41.37% 78.89% -452.33% 164.28% -78.57% -2,088.01% -2.72% 104.61%
Revenue Q/Q Growth		 0.00% 28.99% -27.53% 18.25% -0.52% 0.00% -175.47% 100.00% 0.00%
EBITDA Q/Q Growth		 0.00% -16.80% -1.40% -3.47% -6.45% -413.58% 14.02% 21.72% 173.30%
EBIT Q/Q Growth		 0.00% -15.21% -5.15% -3.37% -4.15% -74.72% 12.57% 21.53% 170.87%
NOPAT Q/Q Growth		 0.00% -15.21% -5.15% -3.37% -4.15% -157.20% 15.25% 14.58% 155.50%
Net Income Q/Q Growth		 0.00% -14.13% -5.46% -4.57% -4.12% -16.59% 11.85% 21.25% 170.84%
EPS Q/Q Growth		 0.00% 77.66% -362.77% -2.56% -7.45% -28.57% 11.85% -31.08% 170.35%
Operating Cash Flow Q/Q Growth		 0.00% -242.28% -24.97% 13.50% -20.69% 2.76% 46.88% -1.06% 13.53%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -6.20% 20.21% -22.92% -144.25% 1,085.48% -83.18% -42.57%
Invested Capital Q/Q Growth		 0.00% 25.83% 67.25% -175.49% 25.03% -63.04% -102.06% -2.48% 104.88%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% -1,131.64% -6,219.99% -4,533.53% -260.49% -83.73% 0.00% 0.00% 56.56%
Operating Margin		 0.00% -1,126.01% -6,599.22% -4,820.98% -282.44% -4,154.64% 0.00% 0.00% 31.45%
EBIT Margin		 0.00% -1,126.01% -6,599.22% -4,820.98% -282.44% -63.34% 0.00% 0.00% 55.49%
Profit (Net Income) Margin		 0.00% -1,044.29% -6,237.46% -4,762.92% -281.90% -156.02% 0.00% 0.00% 55.49%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% -417.78% 100.60% 103.57% 100.00%
Interest Burden Percent		 98.22% 92.74% 94.52% 98.80% 99.81% -58.96% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 59.68% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -642.38% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -671.83% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 639.50% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.51% -37.72% -45.69% -56.63% -52.38% -2.88% -100.92% 145.08% 125.06%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -743.06% -512.96% 0.00% 0.00% -1,661.63%
Operating Return on Assets (OROA)		 0.00% -30.22% -38.60% -45.36% -40.36% -0.92% 0.00% 0.00% 38.70%
Return on Assets (ROA)		 0.00% -28.03% -36.48% -44.82% -40.28% -2.27% 0.00% 0.00% 38.70%
Return on Common Equity (ROCE)		 12.24% -20.09% -45.69% -56.63% -52.38% -2.88% 4.68% 390.81% 125.06%
Return on Equity Simple (ROE_SIMPLE)		 76.02% -28.30% -40.20% -65.66% -56.45% -2.81% 29.38% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -42 -77 -91 -67 -54 -34 -46 17
NOPAT Margin		 0.00% -788.20% -4,619.45% -3,374.69% -197.71% -1,675.04% 0.00% 0.00% 31.45%
Net Nonoperating Expense Percent (NNEP)		 -7.12% -7.91% -11.30% -15.64% -15.32% 29.45% -24.61% -5.50% 24.56%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - 24.32% -252.46% 32.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 325.07% 1,333.19% 1,205.51% 108.43% 1,188.84% 0.00% 0.00% 32.90%
R&D to Revenue		 0.00% 900.94% 5,366.03% 3,715.47% 274.01% 3,065.80% 0.00% 0.00% 35.65%
Operating Expenses to Revenue		 0.00% 1,226.01% 6,699.22% 4,920.98% 382.44% 4,254.64% 0.00% 0.00% 68.55%
Earnings before Interest and Taxes (EBIT)		 -31 -60 -110 -130 -96 -2.03 -53 -46 30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -60 -104 -122 -88 -2.69 -53 -46 30
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 4.27 3.53 2.61 1.23 0.41 0.00 7.38 0.97
Price to Tangible Book Value (P/TBV)		 0.00 4.27 3.53 2.61 1.23 0.41 0.00 7.38 0.97
Price to Revenue (P/Rev)		 0.00 157.54 547.13 189.13 6.12 22.58 0.00 0.00 0.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.37
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 73.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 3.79 0.00 0.00 0.00 0.81
Enterprise Value to Revenue (EV/Rev)		 0.00 117.19 389.63 108.66 1.54 0.00 0.00 0.00 0.04
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13
Enterprise Value to Operating Cash Flow (EV/OCF)		 23.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 27.42 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 -0.62 2.23 0.23
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 -0.60 1.68 0.08
Financial Leverage		 -1.32 -1.17 -1.05 -1.06 -1.02 -0.95 -1.52 0.81 -2.21
Leverage Ratio		 1.40 1.35 1.25 1.26 1.30 1.27 2.59 -2.12 3.23
Compound Leverage Factor		 1.37 1.25 1.18 1.25 1.30 -0.75 2.59 -2.12 3.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -160.65% 69.04% 18.77%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.20% 16.90% 12.05%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -157.45% 52.14% 6.71%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 140.13% 0.00% 0.00% 0.00% 0.00% 0.00% -406.41% 0.00% 0.00%
Common Equity to Total Capital		 -40.13% 100.00% 100.00% 100.00% 100.00% 100.00% 667.06% 30.96% 81.23%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.83 -0.28 0.32
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.35 1.43 -1.27
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.82 -0.21 0.11
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -1.30 -0.27 0.57
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.55 1.41 -2.28
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -1.28 -0.21 0.21
Altman Z-Score		 2.13 7.68 9.42 2.06 -0.18 -0.95 -5.87 -4.07 -0.09
Noncontrolling Interest Sharing Ratio		 140.13% 46.75% 0.00% 0.00% 0.00% 0.00% 104.64% -169.37% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 14.85 9.84 21.54 9.69 11.14 8.02 2.04 4.97 4.85
Quick Ratio		 14.63 9.54 21.20 9.60 9.05 7.75 1.82 4.74 4.26
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -55 -91 -74 -102 -43 28 -45 -46
Operating Cash Flow to CapEx		 330.90% -170.66% -418.44% -2,526.98% -4,580.59% -8,845.21% -373,540.00% -90,286.67% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.03 0.01 0.01 0.14 0.01 0.00 0.00 0.70
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.27 0.04 0.07 1.73 1.93 0.00 0.00 45.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -31 -18 -3.88 -21 14 2.95 -59 -60 2.78
Invested Capital Turnover		 0.00 -0.21 -0.15 -0.21 -8.87 0.38 0.00 0.00 -1.87
Increase / (Decrease) in Invested Capital		 0.00 13 15 -18 35 -11 -62 -1.60 63
Enterprise Value (EV)		 152 624 649 294 52 -103 764 -23 2.26
Market Capitalization		 144 838 912 511 208 72 634 42 41
Book Value per Share		 ($15.91) $5.24 $5.87 $4.33 $2.97 $3.10 ($3.16) $0.47 $3.41
Tangible Book Value per Share		 ($15.91) $5.24 $5.87 $4.33 $2.97 $3.10 ($3.16) $0.47 $3.41
Total Capital		 98 196 259 196 170 178 -27 18 52
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 44 13 9.71
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 43 9.56 3.47
Net Debt		 -130 -215 -262 -217 -156 -175 18 -65 -39
Capital Expenditures (CapEx)		 1.96 25 22 3.73 2.40 1.29 0.01 0.08 -7.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.92 -16 -8.19 -21 19 -17 -10 -9.46 1.64
Debt-free Net Working Capital (DFNWC)		 123 199 254 197 175 158 15 69 50
Net Working Capital (NWC)		 123 199 254 197 175 158 15 65 44
Net Nonoperating Expense (NNE)		 9.23 14 27 38 29 -49 20 1.46 -13
Net Nonoperating Obligations (NNO)		 -130 -215 -262 -217 -156 -175 13 -66 -39
Total Depreciation and Amortization (D&A)		 0.60 -0.30 6.32 7.77 7.46 -0.65 0.59 0.46 0.57
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -292.58% -491.30% -759.62% 55.37% -517.05% 0.00% 0.00% 3.06%
Debt-free Net Working Capital to Revenue		 0.00% 3,742.31% 15,258.28% 7,287.42% 514.21% 4,938.87% 0.00% 0.00% 92.93%
Net Working Capital to Revenue		 0.00% 3,742.31% 15,258.28% 7,287.42% 514.21% 4,938.87% 0.00% 0.00% 81.33%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($217.80) ($36.00) ($44.46) ($50.40) ($31.14) ($1.62) ($35.10) ($5.12) $2.42
Adjusted Weighted Average Basic Shares Outstanding		 137.75K 2.09M 2.51M 2.80M 3.19M 3.19M 3.21M 9.32M 12.30M
Adjusted Diluted Earnings per Share		 ($217.80) ($36.00) ($44.46) ($50.40) ($31.14) ($1.62) ($35.10) ($6.58) $2.42
Adjusted Weighted Average Diluted Shares Outstanding		 137.75K 2.09M 2.51M 2.80M 3.19M 3.19M 3.21M 9.66M 12.31M
Adjusted Basic & Diluted Earnings per Share		 ($217.80) ($36.00) ($44.46) ($50.40) ($31.14) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 137.75K 1.59M 2.34M 2.55M 3.07M 3.20M 3.23M 12.20M 14.63M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -42 -77 -91 -67 -93 -34 -46 12
Normalized NOPAT Margin		 0.00% -788.20% -4,619.45% -3,374.69% -197.71% -2,908.25% 0.00% 0.00% 22.02%
Pre Tax Income Margin		 0.00% -1,044.29% -6,237.46% -4,762.92% -281.90% 37.34% 0.00% 0.00% 55.49%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Q32 Bio

This table displays calculated financial ratios and metrics derived from Q32 Bio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 57,811,083.00 57,934,332.00 58,133,540.00 11,942,129.00 12,059,786.00 12,180,701.00 12,197,615.00 12,197,615.00 12,197,615.00 12,304,352.00 14,629,463.00
DEI Adjusted Shares Outstanding		 3,211,727.00 3,218,574.00 3,229,641.00 11,942,129.00 12,059,786.00 12,180,701.00 12,197,615.00 12,197,615.00 12,197,615.00 12,304,352.00 14,629,463.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.37 -8.41 0.32 -1.42 -1.46 -1.16 -0.90 -0.78 -0.61 4.69 -0.52
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 131.80% -1,928.18% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 58.48% 24.42% 120.30% -174.80% -26.04% 47.49% -900.59% 39.87% 58.41% 513.29% 31.09%
EBIT Growth		 57.50% 22.26% 117.62% -167.42% -25.98% 47.16% -1,015.44% 38.90% 58.01% 507.47% 31.02%
NOPAT Growth		 76.27% 25.18% -187.59% -146.31% -141.27% 43.72% 42.33% 48.82% 59.73% 551.19% 36.85%
Net Income Growth		 58.40% 21.08% 115.05% -192.37% -25.40% 47.58% -1,172.01% 44.11% 58.01% 506.86% 31.02%
EPS Growth		 58.40% 21.08% 68.09% 91.49% 96.40% 98.04% 85.78% 45.07% 58.90% 408.55% 40.00%
Operating Cash Flow Growth		 163.78% 60.61% -16.45% -95.43% -222.77% -6.65% 14.22% 52.05% 78.33% 45.92% 49.18%
Free Cash Flow Firm Growth		 258.10% 427.12% 48.10% -28.88% -47.38% -119.67% -166.72% -155.47% -143.52% -100.51% -155.40%
Invested Capital Growth		 -463.64% -2,088.01% -253.00% -148.77% -102.54% -2.72% 23.10% 11.67% 3.27% 104.61% 105.38%
Revenue Q/Q Growth		 -42.00% -888.70% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 -144.52% -92.70% 105.09% -1,245.76% -12.15% 19.72% 22.39% 13.95% 22.43% 897.81% -112.94%
EBIT Q/Q Growth		 -140.50% -91.99% 104.49% -1,388.71% -13.30% 19.48% 22.14% 13.98% 22.13% 881.30% -113.18%
NOPAT Q/Q Growth		 -7.19% -230.97% 17.84% 15.49% -4.99% 22.79% 15.82% 25.00% 17.38% 964.99% -111.78%
Net Income Q/Q Growth		 -141.62% -92.91% 103.80% -1,749.95% -3.63% 19.36% 22.26% 13.98% 22.13% 881.30% -113.18%
EPS Q/Q Growth		 -141.62% -92.91% 91.84% 77.57% -2.82% -4.11% 40.79% 13.33% 23.08% 881.67% -111.51%
Operating Cash Flow Q/Q Growth		 239.89% -167.39% -35.80% -52.66% 12.12% 41.46% -9.22% 14.67% 60.29% -46.10% -2.64%
Free Cash Flow Firm Q/Q Growth		 -8.98% 38.01% -11.19% -36.25% -32.66% -151.59% -201.26% 47.00% 47.18% -137.71% -283.74%
Invested Capital Q/Q Growth		 -16.11% -102.06% -27.29% 16.70% 5.47% -2.48% 4.71% 4.32% -3.52% 104.88% 11.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 -744.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 107.67% 0.00%
Operating Margin		 -419.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 85.38% 0.00%
EBIT Margin		 -751.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 107.43% 0.00%
Profit (Net Income) Margin		 -754.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 107.43% 0.00%
Tax Burden Percent		 100.47% 100.94% 85.39% 109.33% 100.00% 100.15% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -41.02% -100.92% -45.72% -74.63% -113.82% 145.08% -267.20% -491.67% 55,030.07% 125.06% 157.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,661.63% -1,265.05%
Operating Return on Assets (OROA)		 -32.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 74.92% 0.00%
Return on Assets (ROA)		 -33.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 74.92% 0.00%
Return on Common Equity (ROCE)		 -41.02% 4.68% -45.72% -74.63% -113.82% 390.81% -267.20% -491.67% 55,030.07% 125.06% 157.18%
Return on Equity Simple (ROE_SIMPLE)		 -69.12% 0.00% -94.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.46 -18 -15 -13 -13 -10 -8.56 -6.42 -5.30 46 -5.41
NOPAT Margin		 -293.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 85.38% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.39% -11.10% 10.71% -3.69% -4.55% -15.12% -2.79% -4.43% -3.61% 22.53% -4.56%
Return On Investment Capital (ROIC_SIMPLE)		 - 13.01% -24.23% -27.23% -42.62% -55.48% -98.53% -1,246.54% 73.51% 88.70% -9.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 118.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.45% 0.00%
R&D to Revenue		 401.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.17% 0.00%
Operating Expenses to Revenue		 519.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 14.62% 0.00%
Earnings before Interest and Taxes (EBIT)		 -14 -27 1.21 -16 -18 -14 -11 -9.49 -7.39 58 -7.61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 -27 1.36 -16 -17 -14 -11 -9.35 -7.25 58 -7.49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.77 0.00 1.13 6.40 29.41 7.38 0.00 0.00 0.00 0.97 2.03
Price to Tangible Book Value (P/TBV)		 0.77 0.00 1.13 6.40 29.41 7.38 0.00 0.00 0.00 0.97 2.03
Price to Revenue (P/Rev)		 7.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.76 1.75
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.37 2.83
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 73.00% 35.39%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.81 16.60
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.96
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 1.52
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 1.54
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 2.40
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 27.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 -0.62 0.26 0.37 0.69 2.23 -3.16 -1.04 -0.61 0.23 0.18
Long-Term Debt to Equity		 0.00 -0.60 0.19 0.37 0.61 1.68 -2.00 -0.53 -0.27 0.08 0.04
Financial Leverage		 -1.07 -1.52 -1.48 -1.57 -1.83 0.81 -3.95 -6.51 755.39 -2.21 -2.28
Leverage Ratio		 1.35 2.59 1.75 1.92 2.30 -2.12 5.17 8.95 -1,060.95 3.23 3.37
Compound Leverage Factor		 1.35 2.59 1.75 1.92 2.30 -2.12 5.17 8.95 -1,060.95 3.23 3.37
Debt to Total Capital		 0.00% -160.65% 20.39% 27.25% 40.79% 69.04% 146.21% 2,475.73% -155.69% 18.77% 15.01%
Short-Term Debt to Total Capital		 0.00% -3.20% 5.04% 0.00% 4.96% 16.90% 53.67% 1,209.32% -86.38% 12.05% 11.45%
Long-Term Debt to Total Capital		 0.00% -157.45% 15.35% 27.25% 35.83% 52.14% 92.54% 1,266.41% -69.31% 6.71% 3.56%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -406.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 667.06% 79.61% 72.75% 59.21% 30.96% -46.21% -2,375.73% 255.69% 81.23% 84.99%
Debt to EBITDA		 0.00 -0.83 -0.28 -0.23 -0.22 -0.28 -0.22 -0.25 -0.27 0.32 0.24
Net Debt to EBITDA		 0.00 -0.35 2.74 1.74 1.31 1.43 0.91 0.81 0.91 -1.27 -1.26
Long-Term Debt to EBITDA		 0.00 -0.82 -0.21 -0.23 -0.19 -0.21 -0.14 -0.13 -0.12 0.11 0.06
Debt to NOPAT		 0.00 -1.30 -0.32 -0.27 -0.23 -0.27 -0.29 -0.33 -0.37 0.57 0.38
Net Debt to NOPAT		 0.00 -0.55 3.15 2.05 1.41 1.41 1.19 1.10 1.24 -2.28 -1.99
Long-Term Debt to NOPAT		 0.00 -1.28 -0.24 -0.27 -0.20 -0.21 -0.18 -0.17 -0.16 0.21 0.09
Altman Z-Score		 -4.04 -4.01 -0.60 -0.47 1.01 -2.93 -3.85 -4.89 -5.77 1.40 -0.10
Noncontrolling Interest Sharing Ratio		 0.00% 104.64% 0.00% 0.00% 0.00% -169.37% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.22 2.04 4.19 6.49 6.53 4.97 4.71 5.06 4.57 4.85 5.36
Quick Ratio		 4.08 1.82 4.11 6.26 6.19 4.74 4.49 4.75 4.41 4.26 4.76
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 32 44 39 25 17 -8.57 -26 -14 -7.23 -17 -66
Operating Cash Flow to CapEx		 1,590,100.00% 0.00% 0.00% -148,093.33% -33,658.62% -571,400.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.70 0.75
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 45.75 50.22
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -29 -59 -75 -62 -59 -60 -57 -55 -57 2.78 3.09
Invested Capital Turnover		 -0.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.87 -1.98
Increase / (Decrease) in Invested Capital		 -37 -62 -54 -37 -30 -1.60 17 7.27 1.93 63 61
Enterprise Value (EV)		 -50 764 -68 119 462 -23 -33 -24 -14 2.26 51
Market Capitalization		 68 634 55 214 538 42 20 18 24 41 94
Book Value per Share		 $1.53 ($3.16) $0.84 $2.81 $1.52 $0.47 ($0.33) ($1.00) ($1.51) $3.41 $3.17
Tangible Book Value per Share		 $1.53 ($3.16) $0.84 $2.81 $1.52 $0.47 ($0.33) ($1.00) ($1.51) $3.41 $3.17
Total Capital		 88 -27 61 46 31 18 8.69 0.52 -7.22 52 54
Total Debt		 0.00 44 12 13 13 13 13 13 11 9.71 8.18
Total Long-Term Debt		 0.00 43 9.40 13 11 9.56 8.04 6.52 5.00 3.47 1.94
Net Debt		 -117 18 -123 -95 -76 -65 -53 -42 -38 -39 -43
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.02 0.06 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -22 -10 -27 -13 -8.03 -9.46 -6.77 -1.81 -3.11 1.64 2.02
Debt-free Net Working Capital (DFNWC)		 81 15 108 94 81 69 59 53 46 50 53
Net Working Capital (NWC)		 81 15 105 94 80 65 54 47 40 44 47
Net Nonoperating Expense (NNE)		 8.57 9.00 -16 4.43 4.43 4.02 2.47 3.07 2.09 -12 2.20
Net Nonoperating Obligations (NNO)		 -117 13 -123 -96 -77 -66 -53 -43 -38 -39 -43
Total Depreciation and Amortization (D&A)		 0.13 0.15 0.15 -0.02 0.16 0.17 0.17 0.14 0.14 0.13 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 -249.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.06% 3.76%
Debt-free Net Working Capital to Revenue		 922.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 92.93% 98.20%
Net Working Capital to Revenue		 922.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 81.33% 86.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($10.26) ($1,395.72) $1.03 ($1.42) ($1.46) ($1.52) ($0.90) ($0.78) ($0.60) $4.69 ($0.54)
Adjusted Weighted Average Basic Shares Outstanding		 3.21M 19.39K 995.28K 11.96M 12.08M 9.32M 12.20M 12.20M 12.24M 12.30M 14.10M
Adjusted Diluted Earnings per Share		 ($10.26) ($1,395.72) ($6.33) ($1.42) ($1.46) ($1.52) ($0.90) ($0.78) ($0.60) $4.69 ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 3.21M 19.39K 2.33M 11.96M 12.08M 9.66M 12.20M 12.20M 12.24M 12.31M 14.10M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1,395.72) $0.00 $0.00 $0.00 ($1.52) $0.00 $0.00 $0.00 $4.69 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.22M 3.23M 11.94M 12.06M 12.18M 12.20M 12.20M 12.20M 12.30M 14.63M 16.96M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.46 -18 -10 -13 -13 -10 -8.56 -6.42 -5.30 32 -5.41
Normalized NOPAT Margin		 -293.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 59.76% 0.00%
Pre Tax Income Margin		 -751.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 107.43% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Q32 Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Q32 Bio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Q32 Bio's net income appears to be on a downward trend, with a most recent value of $29.82 million in 2025, falling from -$29.99 million in 2017. The previous period was -$47.73 million in 2024. Find out what analysts predict for Q32 Bio in the coming months.

Q32 Bio's total operating income in 2025 was $16.90 million, based on the following breakdown:
  • Total Gross Profit: $53.74 million
  • Total Operating Expenses: $36.84 million

Over the last 8 years, Q32 Bio's total revenue changed from $0.00 in 2017 to $53.74 million in 2025, a change of 5,373,700,000.0%.

Q32 Bio's total liabilities were at $19.76 million at the end of 2025, a 77.2% decrease from 2024, and a 49.6% decrease since 2017.

In the past 8 years, Q32 Bio's cash and equivalents has ranged from $25.62 million in 2023 to $217.43 million in 2020, and is currently $48.30 million as of their latest financial filing in 2025.

Over the last 8 years, Q32 Bio's book value per share changed from -15.91 in 2017 to 3.41 in 2025, a change of -121.5%.


Related Companies

Financial statements for NASDAQ:QTTB last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than half of his $9 billion portfolio -...
Stansberry Research | Sponsoredtc pixel
Form 10 FILED! *BSEM* BREAKING NEWS
BioStem ($BSEM) has officially filed a Form 10, marking a significant milestone in its path toward becoming an...
Huge Alerts | Sponsoredtc pixel
Elon's Terrifying Warning: America Is "1,000% Going Bankrupt"
The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...
American Hartford Gold | Sponsoredtc pixel